Cognite, a strategy and communications agency, has named Storm Beadle as its new senior account manager, it was reported on Tuesday.
Lee Hurley, executive director at Cognite, said: "We are delighted to welcome Storm to Cognite. She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer's, making her ideally suited to help build successful breakthrough science brands."
Ines Mastrolia has also joined the company as its senior art director following experience in art direction and design.
Malcom Badger, creative director at Cognite, said: "Equally comfortable in print or digital, Ines has a passion for connecting brands to their intended audiences and brings a great mix of flair and skills to her work, attributes which we believe will really benefit our clients and their brands."
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies